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Abstract
Hamman-Rich syndrome is a rapidly progressive interstitial lung disease with acute respiratory distress
syndrome physiology. It carries a grave prognosis and a high early mortality rate. It is often distinguished
from other similar pulmonary pathologies based on the clinical course, laboratory findings, bronchoalveolar
lavage testing, and pathology report. We detail a 77-year-old lady with no prior pulmonary disease, smoking
history, or occupational and environmental exposures present to the emergency department found to be in
acute hypoxic respiratory failure with impressive progressive radiographic findings. The presumptive
diagnosis of Hamman-Rich syndrome was made based on a combination of factors after ruling out other
similar clinical entities, especially in the setting of an ongoing COVID-19 pandemic.
Categories: Pulmonology
Keywords: acute interstitial pneumonia, hamman-rich syndrome, idiopathic interstitial pneumonia, acute respiratory
distress syndrome [ards]
Introduction
Hamman-Rich syndrome, or acute interstitial pneumonia (AIP), is a rare idiopathic pulmonary disease that
leads to fulminant respiratory failure [1]. It was first discovered by Louis Hamman and Arnold Rich in 1935
[2]. AIP's clinical presentation, radiological, and physiological findings are similar to that of acute
respiratory distress syndrome (ARDS). It is characterized clinically by its rapid onset of respiratory failure as
it could often be confused with other clinical entities of interstitial pneumonia. Unfortunately, it has an
extremely poor prognosis with >70% three-month mortality rate despite aggressive medical management
[3].
Case Presentation
Our patient was a 77-year-old lady who presented to the emergency department (ED) with the chief
complaint of shortness of breath. Her past medical history was significant for coronary artery disease (CAD)
status post stent placement, moderate aortic stenosis, depression, and anxiety. She denied a family history
of cardiac or pulmonary conditions. She was fully functional independently at baseline, not on home
oxygen, and denied the use of tobacco, alcohol, or illicit medications. There were no reported recent travel
history or sick contacts. She worked as a florist for many years but denied other occupational or
environmental exposures. Her outpatient medications included Aspirin 81 mg PO daily, clopidogrel 75 mg
PO daily, and fluoxetine 40 mg PO daily. She reported a viral-like illness approximately two weeks ago with
the symptoms of intermittent low-grade fever, non-productive cough, and shortness of breath. Her primary
care physician prescribed albuterol and methylprednisolone without symptomatic relief and thus she
decided to present to the ED for further evaluation. Initial vital signs on ED presentation: temperature max
99.8°F, blood pressure 117/62 mmHg, heart rate 80 beats per minute, respiratory rate 18 breaths per minute,
and pulse oximetry saturation at 97% on 3 liters nasal cannula (NC). Physical examination was overall
benign except for decreased bibasilar breath sounds. Review of systems was negative for chest
pain, orthopnea, paroxysmal nocturnal dyspnea, extremity edema, weight changes, sore throat, chills, night
sweat, or bowel habit changes. Initial laboratory findings were significant for serum sodium 135 mEq/L,
cardiac troponin <0.10 ng/mL, creatinine 0.69 mg/dL, white blood cell count 8.9 K/uL, hemoglobin 14.7 g/dL,
absolute lymphocyte count 1.0 K/uL, d-dimer plasma 433 ng/mL DDU, sedimentation rate 54 mm/h, ferritin
159 ng/mL, C-reactive protein 93.26 mg/L, and negative Abbott RealTime SARS-CoV-2 assay. Chest X-ray
(CXR) showed bilateral patchy asymmetrical opacities without cardiomegaly or pleural effusions (Figure 1).
Computerized tomography (CT) scan of the chest with contrast revealed bilateral patchy ground-glass
opacities without intraluminal defects, cardiomegaly, or pleural effusions (Figure 2). Hologic SARS-CoV-2
assay was sent while the patient was placed in airborne isolation. No antibiotics were administered as there
was a low clinical suspicion of bacterial pneumonia.
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FIGURE 1: Chest X-Ray
Bilateral patchy asymmetrical opacities without cardiomegaly or pleural effusions.
AP: anterior-posterior; L: left.
FIGURE 2: CT Chest (Coronal View)
Bilateral patchy ground-glass opacities without intraluminal defects, cardiomegaly, or pleural effusions.
On days 2-3 of hospitalization, the patient remained afebrile and hemodynamically stable, maintained
oxygen saturation above 90% on 3L NC. The most likely differential diagnosis was COVID-19 pneumonitis
despite the initial negative test result in the setting of the COVID-19 pandemic. She was treated with
methylprednisolone 40 mg b.i.d. while trending the daily inflammatory markers. Blood cultures, sputum
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cultures, urine legionella, and nasal swab Methicillin-resistant Staphylococcus aureus (MRSA) were sent.
She was placed on prophylactic deep venous thrombosis (DVT) regimen and maintained on enhanced
respiratory precautions.
On day 4 of hospitalization, she had worsening of respiratory status and she was placed on a non-rebreather
(NRB) in order to maintain oxygen saturation above 90%. She was subsequently upgraded to the medical
intensive care unit (MICU) due to worsening hypoxic respiratory failure. The clinical assessment of the
patient at this point was believed to be an atypical presentation of COVID-19 pneumonitis despite two
negative COVID-19 assays, mild elevation of the inflammatory markers without up-trending, and a lack of
significant vital signs instability to support cytokine storm. Thus, it was determined to defer the use of
remdesivir and tocilizumab but rather increased methylprednisolone 40 mg to t.i.d. There was a low clinical
suspicion of a cardiogenic component of acute hypoxic respiratory failure as the cardiac B-type natriuretic
peptide (BNP) was 85 pg/mL. Culture data were also negative.
On days 5-13 of hospitalization, her oxygen requirement gradually improved with the treatment of daily
methylprednisolone, albuterol p.r.n., and low dose intravenous furosemide p.r.n. to keep a negative fluid
balance. Bactrim was added to her medical regimen for pneumocystis pneumonia (PCP) prophylaxis in the
setting of steroid treatment. The enhanced respiratory precaution was discontinued as there were three
negative COVID-19 assays. Echocardiogram did not reveal cardiomyopathy or evidence of pulmonary
hypertension. A repeat CT chest with contrast revealed multifocal ground-glass opacities predominately
affecting the right lung in addition to the worsening of the left apical lobe comparing to the previous study
(Figure 3). A detailed autoimmune panel including anti-cyclic citrullinated peptide (anti-CCP), cardiolipin
antibodies, anti-Jo-1 antibody, antinuclear antibody (ANA), and anti-neutrophil cytoplasmic antibody
(ANCA) was sent. She was subsequently downgraded from MICU and was discharged from the hospital while
on 4L NC. She was instructed to continue steroids tapering and follow up with the pulmonologist in the
outpatient setting.
FIGURE 3: CT Chest (Coronal View)
Multifocal ground-glass opacities predominately affecting the right lung in addition to the worsening of the
left apical lobe comparing to the previous study.
The patient was readmitted to the hospital three days after hospital discharge with the chief complaint of
worsening of shortness of breath. Initial vital signs on ED presentation: temperature max 99.0°F, blood
pressure 132/63 mmHg, heart rate 92 beats per minute, respiratory rate 24 breaths per minute, and pulse
oximetry saturation at 88% on NRB. Physical examination revealed increased work of breathing with
decreased bilateral air entry with diffuse rhonchi noted. Initial laboratory findings were significant for:
serum sodium 133 mEq/L, cardiac troponin 0.24 ng/mL without electrocardiogram changes, creatinine 0.72
mg/dL, white blood cell count 22.2 K/uL, hemoglobin 13.9 g/dL, absolute lymphocyte count 0.6 K/uL, d-
dimer plasma 424 ng/mL DDU, cardiac BNP 50 pg/ml, and negative Abbott RealTime SARS-CoV-2 assay.
Arterial blood gas (ABG) revealed pH 7.50, the partial pressure of carbon dioxide (PCO2) 35.1 mmHg, the
partial pressure of oxygen (pO2) 52.7 mmHg, bicarbonate 26.6 mmol/L, lactic acid 2.09 mmol/L. CXR showed
worsening of the bilateral multifocal airspace opacities comparing to prior studies (Figure 4). CT of the chest
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with contrast revealed progression of bilateral alveolar opacities, interlobular septal thickening, and ground-
glass attenuation throughout the lungs without intraluminal defects (Figure 5). The review of systems was
otherwise negative. IV methylprednisolone 40 mg t.i.d. was reinstated along with Bactrim for PCP
prophylaxis. Pan-cultures were also rechecked.
FIGURE 4: Chest X-Ray
Worsening of the bilateral multifocal airspace opacities comparing to prior studies.
L: left; AP: anterior-posterior; UPRT: up-right.
FIGURE 5: CT Chest (Coronal View)
Progression of bilateral alveolar opacities, interlobular septal thickening, and ground-glass attenuation
throughout the lungs without intraluminal defects.
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On day 2 of hospitalization, the patient had worsening of gas exchange and became dyspneic with mild
activities accompanied by brisk oxygen desaturation. She was subsequently upgraded to the MICU with high
flow nasal cannula (HFNC) supplemental oxygen support and ultimately required bilevel positive airway
pressure (BiPAP) ventilation. Flexible bronchoscopy with bronchoalveolar lavage (BAL) revealed scant
secretions, normal bronchial tree anatomy, and pink fluids that were inconsistent with diffuse alveolar
hemorrhage (DAH). Fungal and routine cultures, cytology were sent from BAL fluids. The endotracheal
SARS-COV-2 assay was negative. The transbronchial lung biopsy could not be performed as the patient had
been taking clopidogrel. The patient subsequently had worsening hypoxic respiratory failure requiring
mechanical ventilator support postprocedure. She was managed with low tidal volume support along with a
target plateau pressure <30 cm of water in the setting of an acute respiratory distress syndrome (ARDS)
physiology. She continued to receive steroids, diuretics, and Bactrim while monitoring her respiratory
status.
On day 3-12 of hospitalization, the patient remained to be hemodynamically stable and was tolerating
spontaneous breathing trials (SBT) while on mechanical ventilator support. Connective tissue serologies
along with the autoimmune panel workup were unremarkable. BAL analysis revealed Rothia species along
with 43% fluid neutrophils, 2% fluid lymphocytes, 52% fluid monocytes, 1% fluid eosinophils, and negative
methenamine silver stain. Repeat CXR showed no interval improvement comparing to prior studies (Figure
6). She was subsequently liberated off of invasive mechanical support to BiPAP support successfully after
tolerating a few days of SBT. The patient confirmed her wishes to be placed on hospice directed care after
making the decision of removing her BiPAP support. She remained to be severely dyspneic, frail, and weak
while on HFNC. She unfortunately passed away a few days later. An autopsy was not performed per family
wishes.
FIGURE 6: Chest X-Ray
Stable diffuse interstitial infiltrates with mild heterogeneous alveolar confluence.
Discussion
Hamman-Rich syndrome is often associated with a prodromal illness that lasts around 7-14 days prior to the
rapid onset of respiratory failure [4]. Our patient was in her normal state of health until she developed fever,
non-productive cough, and dyspnea that failed to respond to outpatient management by her primary care
physician thus warranted hospitalization. Initial workup revealed acute hypoxic respiratory failure with
findings of bilateral patchy asymmetrical opacities without cardiomegaly or pleural effusions noted on the
CXR. Her hypoxic respiratory failure had ARDS physiology based on the Berlin definition due to the acuity of
the respiratory symptoms, CXR findings, and the lack of evidence for cardiogenic pulmonary edema based on
her clinical impression, echocardiogram results, and cardiac BNP [5]. Furthermore, routine laboratory
findings are often useful for excluding Hamman-Rich syndrome as certain connective tissue diseases are
associated with interstitial pneumonia that may cause acute exacerbation of respiratory failure [6]. Our
patient had normal laboratory findings of serum muscle enzymes, ANA, anti-Jo-1 antibody, anti-CCP,
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cardiolipin antibodies, and ANCA, thus had a low likelihood of having an underlying connective tissue
disease-related interstitial pneumonia. Moreover, a typical chest imaging of ARDS is important when
formulating the diagnosis of Hamman-Rich syndrome. In a retrospective radiographic chart review
performed by Primack et al. in patients with either biopsy or autopsy-proven Hamman-Rich syndrome, all of
the patients had bilateral air-space opacifications found on the CXR along with ground-glass attenuation
appearance on the CT scans. These findings suggested that the radiographic findings are similar to those of
the ARDS [7]. We were able to perform serial images throughout our patient's hospitalization that revealed
continuous worsening of radiographic findings which correlated with her progressive clinical status. In
addition, it is also important to rule out infectious causes of respiratory failure with microbiologic
investigations from various forms of culture data. However, most patients with Hamman-Rich syndrome
have a non-productive cough that makes it difficult to generate sufficient sputum for analysis. Bronchoscopy
with BAL would then be a useful tool to obtain samples from the respiratory tract [8]. Our patient had
negative culture data to support an alternative infectious process along with a negative methenamine silver
stain that likely ruled out PCP pneumonia. Interestingly, diagnosing Hamman-Rich syndrome in the setting
of the COVID-19 pandemic increases the complexity of the workup due to similar clinical and radiographic
findings. In a retrospective study conducted from three hospitals from the People's Republic of China,
certain patients with confirmed COVID-19 diagnosis had CT chest findings of extensive ground-glass
opacities and consolidations in both lungs [9]. Our patient's initial diagnosis revolved around a possible
atypical presentation of COVID-19 pneumonitis despite an initial negative Abbott RealTime SARS-CoV-2
assay. However, COVID-19 pneumonitis was later eliminated from the differential diagnosis as future
COVID-19 testings were negative.
Bronchoscopy with BAL is an important tool used to exclude other diseases with similar clinical
presentations. The cellular profile found in Hamman-Rich syndrome is often non-specific. In a retrospective
chart review conducted in patients with histologically proven Hamman-Rich syndrome, some of the patients
had an increase in neutrophil percentage similar to our patient, although the finding could be non-specific
[8]. However, we were able to effectively rule out other pulmonary conditions with similar
presentations. Diffuse alveolar hemorrhage (DAH) was eliminated from the differential diagnosis based on
the lack of alveolar hemorrhage found during the procedure [10]. Acute eosinophilic pneumonia (AEP) was
determined to be unlikely based on the 1% fluid eosinophils noted in the fluids as BAL fluid typically reflects
>25 percent of eosinophils in AEP [11]. Furthermore, hypersensitivity pneumonitis (HP) was a compelling
alternative diagnosis in this patient due to her occupation as a florist along with similar CT chest findings. In
contrast to Hamman-Rich syndrome, HP is often associated with marked lymphocytosis (>20%) found on
BAL in the subacute phase [12]. Typical CT chest findings could show centrilobular nodules with ground-
glass attenuation with upper lung predominance depending on the disease phase [13, 14]. There were only
2% lymphocytes found in the BAL fluids of our patient along with a lack of centrilobular nodules and upper
lobe predominance findings based on the CT scan.
One of the limitations of our case report is the lack of histological evidence. The transbronchial biopsy was
not attempted as she was taking clopidogrel in the setting of prior stent deployment. Furthermore, there
were discussions of potentially performing a video-assisted or open lung biopsy but later was deemed
unnecessary as the patient was medically unstable and later pursued hospice directed care. Hamman-Rich
syndrome has the histopathologic appearance of diffuse alveolar damage with phases of acute exudative,
organizing proliferative, and fibrosis. The exudative phase develops within first week of the injury that is
characterized by intra-alveolar edema, hyaline membrane formation, and interstitial infiltrate of
inflammatory cells. Moreover, the proliferative phase occurs one week after the exudative phase that is
associated with fibroblastic proliferation throughout the alveolar sac and interstitium. Extensive fibrosis and
the organization process is seen histologically in the final phase [3].
Conclusions
Hamman-Rich syndrome is often a diagnosis of exclusion in the setting of sudden onset of fulminant acute
hypoxic respiratory failure with ARDS physiology. Despite histological evidence is important for diagnosis
confirmation, the ability to narrow down the differential diagnosis in the proper clinical setting is an
essential tool that clinicians should utilize in order to formulate a likely diagnosis and subsequent treatment
plan. Using objective data from laboratory findings, bronchoscopy with BAL, and radiographic findings are
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